[go: up one dir, main page]

SV2018005730A - Biomarcadores para copanlisib - Google Patents

Biomarcadores para copanlisib

Info

Publication number
SV2018005730A
SV2018005730A SV2018005730A SV2018005730A SV2018005730A SV 2018005730 A SV2018005730 A SV 2018005730A SV 2018005730 A SV2018005730 A SV 2018005730A SV 2018005730 A SV2018005730 A SV 2018005730A SV 2018005730 A SV2018005730 A SV 2018005730A
Authority
SV
El Salvador
Prior art keywords
copanlisib
progression
patients
nhl
biomarkers
Prior art date
Application number
SV2018005730A
Other languages
English (en)
Inventor
Li Liu
Carol Pena
Jie Cheng
Karl Köchert
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2018005730A publication Critical patent/SV2018005730A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA BIOMARCADORES QUE SE BASAN EN LOS PERFILES DE EXPRESIÓN GÉNICA LOS CUALES PUEDEN DISCRIMINAR ENTRE PACIENTES QUIENES RESPONDEN AL TRATAMIENTO CON COPANLISIB Y/O CON SUPERVIVENCIA MÁS LARGA LIBRE DE PROGRESIÓN Y PACIENTES QUIENES NO RESPONDEN AL TRATAMIENTO CON COPANLISIB Y/O CON SUPERVIVENCIA MÁS CORTA LIBRE DE PROGRESIÓN EN LINFOMA QUE INCLUYE LNH INDOLENTE Y AGRESIVO Y LLC. LA PRESENTE INVENCIÓN SE REFIERE AL USO DE GENES DE LOS PROCESOS DEL BCR, PI3K, NFKB, IL6, INFLAMACIÓN Y ESTROMALES COMO BIOMARCADORES PREDICTIVOS DE DIVERSOS CÁNCERES HUMANOS QUE INCLUYEN, ENTRE OTROS, LOS LNH
SV2018005730A 2016-02-01 2018-08-07 Biomarcadores para copanlisib SV2018005730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662289713P 2016-02-01 2016-02-01
US201662376017P 2016-08-17 2016-08-17

Publications (1)

Publication Number Publication Date
SV2018005730A true SV2018005730A (es) 2018-12-05

Family

ID=57984901

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005730A SV2018005730A (es) 2016-02-01 2018-08-07 Biomarcadores para copanlisib

Country Status (16)

Country Link
US (1) US20190038632A1 (es)
EP (1) EP3411497A1 (es)
JP (1) JP2019511204A (es)
KR (1) KR20180101603A (es)
CN (1) CN108884496A (es)
AU (1) AU2017214230A1 (es)
BR (1) BR112018015782A2 (es)
CA (1) CA3012890A1 (es)
CL (1) CL2018002069A1 (es)
MA (1) MA43957A (es)
MX (1) MX2018009368A (es)
PH (1) PH12018501623A1 (es)
SG (2) SG11201806274SA (es)
SV (1) SV2018005730A (es)
TN (1) TN2018000271A1 (es)
WO (1) WO2017134000A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107864625B (zh) 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN109729716B (zh) 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
PE20200958A1 (es) * 2017-09-08 2020-09-24 Bayer Consumer Care Ag Solido liofilizado de copanlisib
WO2020092860A1 (en) * 2018-11-01 2020-05-07 The Jackson Laboratory Gastric cancer treatments
EP4231872A4 (en) 2020-10-21 2024-11-27 Black Jet Innovations, Inc. HANDLE AND STAND FOR A MOBILE DEVICE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
UA119537C2 (uk) * 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
TW201819923A (zh) * 2013-06-20 2018-06-01 日商大鵬藥品工業股份有限公司 基於ＰＨＬＤＡ１或ＰＩＫ３Ｃ２Ｂ表現之ＰＩＫ３／ＡＫＴ／ｍＴＯＲ抑制劑之治療效果的預測方法
SG10201807838SA (en) * 2014-03-11 2018-10-30 Council Queensland Inst Medical Res Determining cancer aggressiveness, prognosis and responsiveness to treatment
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法

Also Published As

Publication number Publication date
TN2018000271A1 (en) 2020-01-16
MA43957A (fr) 2018-12-12
SG11201806274SA (en) 2018-08-30
CL2018002069A1 (es) 2018-11-16
JP2019511204A (ja) 2019-04-25
BR112018015782A2 (pt) 2019-01-02
CN108884496A (zh) 2018-11-23
EP3411497A1 (en) 2018-12-12
KR20180101603A (ko) 2018-09-12
SG10202007262PA (en) 2020-09-29
MX2018009368A (es) 2018-09-05
AU2017214230A1 (en) 2018-08-09
PH12018501623A1 (en) 2019-06-03
CA3012890A1 (en) 2017-08-10
WO2017134000A1 (en) 2017-08-10
US20190038632A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
SV2018005730A (es) Biomarcadores para copanlisib
SV2018005729A (es) Biomarcadores de copanlisib
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
ECSP17005276A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR095233A1 (es) Métodos y composiciones para el control de malezas
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
CL2016003260A1 (es) Profármacos de gemcitabina
CR20150316A (es) Compuestos y sus métodos de empleo
MX2015003140A (es) Formulaciones de enzalutamida.
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
CL2016002223A1 (es) Microorganismo recombinante que expresa análogos de avermectina y uso de los mismos.
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
CL2017001487A1 (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr.
MX2018006790A (es) Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos.
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos
CL2018003013A1 (es) Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.
MX2018003313A (es) Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.
TWD186330S (zh) 出口裝置
TR201718258A2 (tr) Tamoksifen dirençli meme kanseri tedavisi için geliştirilen yeni stratejiler.